Evidence map›Paper›PMID 31949758›Full record

ArticleInternational journal of clinical and experimental pathology2018

Genotypicdiversity of drug-resistant

Yuling Wang, Hong Xu, Yanan Li, Huixia Gao, Zhi Zhang, Yuzhen Liu, Jianhua Lu, Erhei Dai

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yuling WangDepartment of Tuberculosis, The Fifth Hospital of Shijiazhuang, Hebei Medical University Shijiazhuang, Hebei, China.
Hong XuDepartment of Laboratory Medicine, The Fourth Hospital of Shijiazhuang, Shijiazhuang Obstetrics and Gynecology Hospital Shijiazhuang, Hebei, China.
Yanan LiDepartment of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University Shijiazhuang, Hebei, China.
Huixia GaoDepartment of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University Shijiazhuang, Hebei, China.
Zhi ZhangDepartment of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University Shijiazhuang, Hebei, China.
Yuzhen LiuDepartment of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University Shijiazhuang, Hebei, China.
Jianhua LuDepartment of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University Shijiazhuang, Hebei, China.
Erhei DaiDepartment of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University Shijiazhuang, Hebei, China.
Hebei Medical University · CNFirst Hospital of Shijiazhuang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-resistant tuberculosis (DR-TB), particularly multidrug-resistant tuberculosis (MDR-TB), has been identified as a major challenge for effective TB control. For rapid detection and proper treatment, molecular assays based on the identification of mutations in genes associated with drug resistance have been established to determine drug resistance. However, there is as yet little information about drug resistance-associated mutations of clinical

Indexed as

drug resistancegene mutationMycobacterium tuberculosis

Identifiers

PMID31949758
PMCPMC6962832
OpenAlexW3026059069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.